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Abstract
Morbi-mortality in cystic fibrosis (CF) is mainly related to chronic lung infection and inflammation, uncontrolled tissue
rearrangements and fibrosis, and yet the underlying mechanisms remain largely unknown. We evaluated inflammatory and
fibrosis responses to bleomycin in F508del homozygous and wild-type mice, and phenotype of fibroblasts explanted from
mouse lungs and skin. The effect of vardenafil, a cGMP-specific phosphodiesterase type 5 inhibitor, was tested in vivo and in
culture. Responses of proinflammatory and fibrotic markers to bleomycin were enhanced in lungs and skin of CF mice and
were prevented by treatment with vardenafil. Purified lung and skin fibroblasts from CF mice proliferated and differentiated
into myofibroblasts more prominently and displayed higher sensitivity to growth factors than those recovered from wild-
type littermates. Under inflammatory stimulation, mRNA and protein expression of proinflammatory mediators were higher
in CF than in wild-type fibroblasts, in which CFTR expression reached similar levels to those observed in other non-epithelial
cells, such as macrophages. Increased proinflammatory responses in CF fibroblasts were reduced by half with
submicromolar concentrations of vardenafil. Proinflammatory and fibrogenic functions of fibroblasts are upregulated in
CF and are reduced by vardenafil. This study provides compelling new support for targeting cGMP signaling pathway in CF
pharmacotherapy.
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Introduction
Cystic Fibrosis (CF), an inherited disorder due to mutations of
the CF Transmembrane conductance Regulator (CFTR) gene, has a
complex phenotype with multiple clinical manifestations; but lung
disease, characterized by chronic airway obstruction, infection and
inflammation, accounts for the major cause of morbi-mortality.
Fibrosis of the pancreas was recognized since the description of the
disease [1]. Extensive pulmonary fibrosis is a common finding in
end-stage CF lung disease, and tissue remodelling with increased
collagen deposition has been demonstrated in distal airways of
young children with CF [2].
Fibroblasts form a heterogeneous population of interstitial
stromal cells, the major functions of which are production of
extracellular matrix maintaining parenchymal tissue architecture
and regulating fibroproliferative repair. However, it has been
recognized that fibroblasts may provide much more than a scaffold
for parenchymal tissue. They are indeed able to secrete powerful
inflammatory chemoattractants, including chemokine C-C ligand
(CCL)-2 and -8, monocyte chemotactic protein-1 and -2,
interleukin-(IL)-16, RANTES and IL-8 [3,4]. The contribution
of fibroblasts to the pathogenesis of autoimmune diseases, such as
rheumatoid arthritis and Graves’ disease, has been recently
recognized [5,6].
Excess fibrogenesis in CF is not understood and may represent a
target therapy. We hypothesized that fibroblast dysfunctions
represent a major characteristic of CF. To test this new hypothesis,
we investigated the phenotype of lung and skin fibroblasts from
mice homozygous for F508del, the most common CFTR mutation
[7]. Markers of inflammatory and fibrotic responses, and
pathology studies in lungs and skin were analyzed in in vivo models
of bleomycin-induced fibrosis. Cell proliferation and differentia-
tion into myofibroblasts, a specialized type of fibroblasts activated
during wound healing, and expression of inflammatory mediators
were investigated in purified cultured lung and skin fibroblasts. We
also analyzed whether these responses are influenced by
vardenafil, a clinically approved cGMP-dependent phosphodies-
terase type 5 inhibitor (PDE5i). Vardenafil was tested based on its
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potential application in CF: we have previously shown that it is
able to increase defective F508del-CFTR dependent chloride
transport across the mouse nasal mucosa [8,9] and to prevent
inflammation [10]. In this work we show, for the first time, that CF
fibroblasts display an altered phenotype with increased prolifer-
ation and myofibroblast differentiation, higher sensitivity to
growth factors and overresponses of proinflammatory and fibrotic
mediators. Vardenafil prevents dysregulated fibroblast responses;
this highlights its potential in CF pharmacotherapy.
Methods
Animal Models
Adult female 129/FVB Cftrtm1EUR mice homozygous for the
F508del mutation [7] and C57Bl6 CftrUNC knockout mice were
housed under conventional conditions [11]. Bleomycin (Sanofi,
Diegem, Belgium) and vardenafil HCl (Bayer, West Haven,
Germany), prepared in saline, were administered by pharyngeal
aspiration into the lungs, topical skin injection or intraperitoneal
injection. The experimental protocol was approved by the local
ethical committee for animal research at the Universite´ catholique
de Louvain (2010/UCL/MD/034) and conformed to the
European Community regulations (CEE nu 86/609).
Bronchoalveolar Lavage (BAL) and Lung Histology
BAL was performed as described [12]. Unlavaged lungs were
inflated with 3.6% paraformaldehyde for pathology studies.
Paraffin-embedded 5-mm sections were stained with hematoxylin
and eosin or Masson’s Trichrome or were impregnated with silver.
Collagen and Cytokines
Collagen was measured as described [13]. Mouse CCL-2, IL-6,
transforming growth factor (TGF)-b1 and tissue inhibitor of
metalloproteinase (TIMP)-1 were assessed by ELISA (R&D
Systems, Abingdon, UK); limits of detection were 1.9, 3.9, 3.9
and 7.8 mg/ml, respectively.
Cell Cultures
Perfused lungs and skin explants were digested with Liberase
TH (4 mg/lung; 1.3 mg/skin explant; Roche, Vilvoorde, Belgium)
and DNAse (250 mg/lung; 83 mg/skin explant; Gestimed, Brus-
sels, Belgium) and cultured in DMEM with 10% FBS (Life
technologies, Gent, Belgium) [14]. Proliferation was estimated by
3H-thymidine (Amersham, Gent, Belgium) incorporation or daily
counting of cultured cells. Inflammatory challenging of fibroblasts
was performed with 0.1 mg/ml lipopolysaccharide from Pseudomo-
nas aeruginosa (LPS; Sigma Aldrich, Diegem, Belgium); 20 ng/ml
mouse recombinant IL-1b; LPS plus 0.1 mg/ml mouse recombi-
nant interferon (IFN)-c or IL-4 plus IL-13 (10 ng/ml of each).
Vardenafil (0.1 to 50 mM) was added to fibroblast cultures.
Protocols for culturing nasal epithelial cells, alveolar and
peritoneal macrophages are detailed in Methods S1.
Flow Cytometry
Fluorescent surface labelling of fibroblasts were performed
using antibodies against a-smooth muscle actin (SMA, clone
1A4; Sigma Aldrich), type I collagen (clone M19; Santa Cruz,
Heidelberg, Germany), CD45 (clone 30-F11; BD Biosciences,
Erembodegem, Belgium) and CD11c (clone HL3; BD Biosci-
ences). Fc receptors were blocked with anti-CD16/32 (clone
2.4G2, BD Biosciences) to reduce nonspecific binding. Samples
fixed in 1.25% paraformaldehyde were analyzed using FlowJo
software (Ashland, OR, USA).
Quantitative RT-PCR
RNA, extracted with TripureHReagent (Roche, Vilvoorde,
Belgium), was reverse transcribed and resulting cDNA was used
as a template in subsequent RT-PCR analysis. Sequences of
interest were amplified using the forward and reverse primers
(Table S1).
Immunoprecipitation
Immunoprecipitation was performed in fibroblast lysates after
incubation with mouse anti-CFTR antibody clone 24-1 (R&D
Systems) coupled with G protein-conjugated magnetic Dynabeads
(Invitrogen, Merelbeke, Belgium). CFTR was detected on Western
blots using an Odyssey LI-COR platform (Lincoln, NE, USA).
Immunostaining
Immunostaining of CFTR was performed in fibroblasts grown
on collagen-coated cover glasses using a mouse anti-CFTR (clone
24-1) and an anti-mouse AlexaFluor 488 secondary antibody (Life
technologies). Images obtained by an AxioImager microscope
were processed using AxioVision Release 4.8.2.0 software.
Statistics
Between-group comparisons were performed by ANOVA
(GraphPad InStat; San Diego, CA, USA). Posthoc comparisons
were made using Student’s t test or Tukey-Kramer HSD test, as
adequate. Null hypothesis was rejected at P,0.05.
Results
Exaggerated CF Lung Responses to Bleomycin
To test whether fibrosis is affected in CF lungs, we applied an
in vivo mouse model of pulmonary fibrosis induced by bleomycin
[12], a glycopeptide antibiotic commonly used as cancer
chemotherapy. Under control conditions, apart from CCL-2
levels which were twice as high in BAL of CF compared to wild-
type mice (Figure 1c), no genotype-related differences were
detected (Figure 1). After bleomycin (0.015 U per mouse),
unexpectedly high (.90%) mortality was observed in CF but
not in wild-type animals, that survived up to at least day 21. At day
10, the last day at which no mortality had still been observed, the
magnitude of responses to bleomycin differed with genotype. In
the wild-type group, profibrotic mediators, TGF-b1 and TIMP-1
were increased after bleomycin compared to the levels monitored
in naive conditions; changes after challenge were more pro-
nounced in CF (Figure 1e,f). Collagen content in whole lung
homogenates was about twice as high in bleomycin-treated CF
animals as in any other group (Figure 1a). Lymphocyte (Figure 1b)
and neutrophil (data not shown) infiltration was higher in
bleomycin-treated CF mice. Bleomycin-induced release of CCL-
2 and IL-6 into BAL were three times larger in CF than in non-CF
mice (Figure 1c,d). TGF-b1 and TIMP-1 were 2- and 4-fold larger
in CF than in wild-type mice (Figure 1e,f). Bleomycin induced
marked lung morphological changes (Figure 2). Alveolar spaces
were obliterated by accumulation of fibroblasts and inflammatory
cells, together with collagen deposition (Figure 2f,h inserts).
Changes were more prominent in CF mice, in particular
deposition of collagen III-rich argyrophilic fibres in areas of tissue
condensation (Figure 2f,h).
To test whether vardenafil modulates bleomycin-induced
responses, animals were treated with this PDE5i selected because,
compared to sildenafil, it is more soluble, more potent and has a
longer lasting effect on activation of F508del-CFTR protein [8,9].
Vardenafil treatment lowered CF overreactions down to the same
level as in wild-type, no significant changes being observed in the
Vardenafil, Inflammation and Fibrosis in CF
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wild-type group (Figure 1a–f). Vardenafil reduced extent and
severity of histopathological inflammatory and fibrotic transfor-
mations in CF and wild-type lung sections of mice treated with
bleomycin (Figure 2i–l). The data indicate that F508del-CFTR
mutation is associated with exaggerated airway inflammatory and
fibroproliferative repair processes that can be prevented by
treatment with vardenafil.
Mouse Fibroblasts Express CFTR Protein
Before testing the hypothesis that F508del-CFTR is associated
with altered fibroblastic functions, we first examined CFTR
expression in purified fibroblasts from wild-type lungs. Epithelial
cells strongly express CFTR. Macrophages express CFTR at a low
but functional level [15]. A functionally altered [16,17] but
controversial [18,19] phenotype has been recognized in dermal
fibroblasts from CF patients. To investigate CFTR protein and
mRNA expression, comparative analyses were performed in
mouse fibroblasts, macrophages and epithelial cells from different
origins. Lower CFTR protein expression was found in F508del-CF
than in wild-type fibroblasts; fibroblasts isolated from Cftr knockout
mice showed no detectable expression (Figure 3a,b). CFTR
mRNA expression in wild-type lung fibroblasts showed levels
similar to those found in 3T3 cell line. Cell passage did not seem to
affect CFTR expression as quite similar protein expression levels
were observed at the second and the third passages (Figure 3c).
Similar levels were also observed in J774 cells, in alveolar and
peritoneal macrophages. Predictably, CFTR was highly expressed
in airway epithelial cells (Figure 3c; Methods S1). These data
indicate that similar CFTR expression is found in fibroblasts as in
other non-epithelial cells, such as macrophages.
Proliferation and Myofibroblast Differentiation of CF
Lung Fibroblasts
All experiments using cultured fibroblasts were performed at the
second passage when 86% of cultured cells were negative for
CD45 leukocyte-specific cell-surface marker, more than 40% of
cells were positive for type I collagen and a-SMA, and less than
Figure 1. Exaggerated CF lung responses to bleomycin are attenuated by vardenafil. a) Soluble collagen content in homogenized
unlavaged lungs; b) lymphocyte counts, c) CCL-2, d) IL-6, and e) TGF-b1 in bronchoalveolar lavage (BAL); and f) TIMP-1 in homogenized unlavaged
lungs from CF mice homozygous for the F508del mutation and from wild-type (WT) mice 10 days after deposition into the lungs by pharyngeal
aspiration of a single dose of 0.015 U bleomycin (Bleo). In case of simultaneous treatment with bleomycin and vardenafil, animals were given a first
intraperitoneal injection of 0.14 mg/kg vardenafil (Vard) on the day before the bleomycin dose and every day thereafter until the day before
sampling. Values are means 6 SEM of 5 animals per group from a representative experiment selected from a series of 3 experiments with similar
results. *: P,0.05; **: P,0.01; *** P,0.001 for comparison of mean values.
doi:10.1371/journal.pone.0064341.g001
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3% CD11c positive cells, indicating macrophage contamination,
were found (data not shown).
To test the hypothesis that F508del-CFTR mutation is
associated with altered fibroblastic functions, we examined cell
proliferation and myofibroblast differentiation in purified cultured
fibroblasts from lungs of CF and wild-type mice. 3H-thymidine
incorporation was higher in CF than in wild-type fibroblasts, even
in the absence of any added growth factor (Figure 4a). In the
presence of human recombinant platelet-derived growth factor
(rPDGF)-BB, thymidine incorporation increased in a dose-
dependent manner, reaching higher values in CF fibroblasts
(Figure 4a). Cell growth curve analysis, assessed by daily counting
of trypsinized cells in culture, showed higher density at a plateau
phase in CF fibroblasts (Figure 4b). Expression of a-SMA, a
marker of differentiation towards a myofibroblast phenotype, was
higher in CF fibroblasts, even in naive conditions (Figure 4c,d).
The stimulating effect of human rTGF-b1 on a-SMA expression
was increased in CF compared to wild-type fibroblasts (Figure 4c).
Vardenafil did not modify cell growth (data not shown) but
decreased a-SMA mRNA expression in both CF and non-CF
Figure 2. Lung histological responses to bleomycin are attenuated by vardenafil. Lung histological sections of wild-type (a,b,e,f,i,j) and CF
mice homozygous for the F508del mutation (c,d,g,h,k,l) 10 days after treatment with saline (NaCl; a–d), bleomycin (Bleo; e–h) or bleomycin and
vardenafil (Bleo+Vard; i–l) were stained with hematoxylin and eosin (a,c,e,g,i,k); impregnated with silver (b,d,f,h,j,l) or stained with Masson’s trichrome
(inserts). Bars, 100 mm in panels a,c,e,g,i,k; 20 mm in panels b,d,f,h,j,l; and 40 mm in inserts. Representative micrographs from 5 mice per group.
doi:10.1371/journal.pone.0064341.g002
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fibroblasts (Figure 4d). In the presence of 50 mM vardenafil, a-
SMA expression in CF fibroblasts reached levels as low as those
monitored in similarly treated wild-type cells. These findings
indicate that CF lung fibroblasts display a modified extracellular
matrix producing phenotype in naive conditions and under
stimulation by growth factors, and that vardenafil inhibits this
phenotype in CF and in non-CF lung fibroblasts.
Dysregulated Fibrogenic Processes in CF are not Solely
Confined to Lung Fibroblasts
To test whether altered fibroblast properties are confined to
lung fibroblasts, we examined histopathology in response to
bleomycin, fibroblast proliferation and myofibroblast differentia-
tion in another tissue. Histological analyses of skin lesions after
topical application of bleomycin (Methods S1) confirmed in-
creased neofibrogenesis in CF animals with a dermis containing
more numerous inflammatory cells and collagen III-rich argyro-
philic fibres, whereas bleomycin-challenged wild-type tissues were
more scarred (Figure S1). In addition, epidermal layer and hair
follicles were hyperplastic. The changes were reduced in
vardenafil-treated animals.
Cultured CF dermal fibroblasts showed, as observed in CF lung
fibroblasts, increased proliferation (Figure 4e,f) and differentiation
into myofibroblasts (Figure 4g). As for lung fibroblasts (Figure 4c,d),
baseline a-SMA overexpression and TGF-b1 hypersensitivity were
Figure 3. Mouse fibroblasts express CFTR protein. CFTR expression in mouse nasal epithelial cells in primary cultures, fibroblasts (3T3 cell line
and lung cells at passages #2 and #3) and macrophages (J774 cell line and alveolar and peritoneal cells in primary cultures). a) Immunoblots of
precipitates for IgG blank and lung fibroblasts from Cftr knockout mice (KO), wild-type (WT) and CF mice homozygous for the F508del mutation.
Immunoprecipitates (IP) using 46106 fibroblasts grown in Petri dishes were lysed in a buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100)
supplemented with Complete PIC (Roche) and incubated with mouse anti-CFTR antibody clone 24-1 coupled with G protein-conjugated magnetic
Dynabeads. Data selected from at least 4 experiments with similar results. As expected for mouse CFTR, a band was recognized at 160 kDa but not
detected when IPs were performed with non-immune IgG. b) Immunofluorescence labelling for CFTR (green) in fibroblasts purified from Cftr
knockout (KO) mice, wild-type mice with (WT) or without CFTR antibody (w/o Ab), and CF mice homozygous for the F508del mutation. Fibroblasts
grown on collagen-coated cover glasses were fixed with acetone and permeabilized with 0.25% Triton X-100. Detection was obtained using anti-
mouse AlexaFluor 488 secondary antibody after overnight incubation with anti-CFTR antibody clone 24-1. Nuclei stained with DAPI blue. Bars: 20 mm.
Data selected from at least 3 experiments with similar results. c) Total CFTR mRNA expression, using 18S rRNA as a reference. Data expressed as
means 6 SEM of 3–8 samples per group.
doi:10.1371/journal.pone.0064341.g003
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noted in CF skin fibroblasts (Figure 4g). The exacerbated capacity
of CF cells to differentiate into myofibroblasts was also illustrated
by formation, in CF cultures, of cellular aggregates indicating cell
contracture activity (Figure 4h). These findings indicate that
dysregulated fibrogenic processes in CF are not solely confined to
lung fibroblasts.
Proinflammatory Status of CF Fibroblasts and Preventing
Effect of Vardenafil
We then investigated whether fibroblasts play a role in the
exaggerated inflammatory responses in CF. Under non-stimulated
conditions, CCL-2 mRNA expression was enhanced in CF lung
fibroblasts (Figure 5a). After stimulation with LPS, kinetics of the
transcript showed higher levels in CF lung fibroblasts peaking 6 h
after stimulation (Figure 5a). LPS-induced CCL-2 transcript was
also increased in CF compared to wild-type skin fibroblasts
(Figure 5d). Accordingly, LPS-induced CCL-2 protein release was
larger in CF than in wild-type dermal fibroblasts (Figure 5c).
Responses to LPS of other proinflammatory markers, such as
TNF-a, IL-1b and IL-6, were increased in CF compared to non-
CF lung fibroblasts (Figure 5e–g). CF overresponses were also
observed under the influence of other proinflammatory stimuli,
such as mouse rIL-1b (Figure S2a). Moreover, responses of TNF-a
and inducible nitric oxide synthase (iNOS) driven by a F1
polarization protocol, consisting on a combination of LPS plus
IFN-c were increased in CF compared to wild-type lung
fibroblasts (Figure S2b,c). However, the anti-inflammatory Ym1-
2 chitinase-like protein after stimulation with a F2 protocol,
consisting in the combination of IL-4 plus IL-13 stimuli, did not
show any difference between CF and non-CF cells (Figure S2d).
To test whether vardenafil reduces proinflammatory responses
in CF and non-CF lung and dermal fibroblasts, we first assessed
CCL-2 transcripts after treatment with the PDE5i. The LPS-
stimulating effect was inhibited by 0.1 mM vardenafil, no
additional inhibitory effect being observed with larger concentra-
tions (Figure 5b,d). Vardenafil (0.1 mM) also downregulated TNF-
a, IL-1b and IL-6 mRNA expression in CF lung fibroblasts, with
no effect in non-mutated cells. These findings indicate that CF
fibroblasts from different tissue origins display an overresponsive
proinflammatory status and that vardenafil prevents fibroblast
inflammatory responses.
Discussion
The present study was designed to test the hypothesis that
fibroblasts represent master cells in fibrogenesis in CF. Clinical
studies have suggested that uncontrolled airway remodelling in CF
begins early in life [2,20]. Ultrastructural changes of airway
scarring, including thickening of epithelial basement membrane
and collagenisation of lamina propria, have been linked to a worse
pulmonary outcome [21]. Additional evidence emerges from the
demonstration that overexpression of TGF-b1, a key growth factor
for fibroblast functions, is associated with a more severe CF lung
phenotype [22]. Studies on polymorphisms of TGF-b1 have given
rise to the suggestion that the gene is a modifier of CF lung
function [23]. However, mediators of fibrosis events in CF are not
understood.
We show an increased release into CF lungs of TGF-b1, a
multi-functional protein involved in wound repair, myofibroblast
differentiation and synthesis of several components of connective
tissue matrix [24]. In CF lungs challenged with bleomycin,
overexpression of TIMP-1, an early and predictive marker of
tissue remodelling [25], reflects a protease/antiprotease imbalance
associated with tissue damage. Increased basal CCL-2 expression
in CF mice is in line with the increased levels we have previously
demonstrated in the bronchoalveolar and peritoneal compart-
ments of CF mice [13]. The enhanced lymphocyte and neutrophil
lung infiltrates denote that fibrosis in CF involves multiple cell
types. CF mice challenged with bleomycin display exaggerated
proinflammatory and matrix accumulation responses. Histological
changes in lungs and skin included increased inflammatory
infiltration and matrix neoformation with reticulinic fibres
accumulation. Accordingly, excessive skin fibrosis and epidermal
thickening have been reported in F508del-CF mice during mite
infestation [26].
The assumption that function of fibroblasts is solely related to
their capacity to produce extracellular matrix has been revisited,
based on recent demonstrations of their critical roles in
pathogenesis of autoimmune diseases [5,6]. However, the exact
role of fibroblasts in inflammation has not been fully clarified.
Data presented here clearly show, for the first time, that purified
cultured fibroblasts from CF tissues have an altered phenotype. CF
fibroblasts proliferate exaggeratedly, overreact to PDGF-BB and
TGF-b1 and display increased myofibroblat differentiation with
neoexpression of a-SMA, the actin isoform related to contractile
activity in vascular smooth muscle cells [24]. This work confirms
CCL-2 dysregulation in CF immune responses [13] and suggests
that different cell populations contribute to chemokine overpro-
duction in CF: we have previously shown that CF alveolar and
peritoneal macrophages [13], but not CF respiratory epithelial
cells [27], produce manifold larger amounts of CCL-2 than non-
CF cells. Overproduction of multiple proinflammatory mediators
(CCL-2, TNF-a, IL-1b, IL-6), triggered by different stimuli (IL-1b,
LPS and IFN-c) in fibroblasts from different (lung and dermal)
origins, denotes that the proinflammatory status in CF fibroblasts
is a ubiquitous, extensive and complex process involving multiple
signalling pathways and transcription factors that may act
separately or in concert.
CFTR expression in CF fibroblasts has not been thoroughly
investigated. It has been observed, using northern analysis, in non-
epithelial cells including lung fibroblasts, monocytes and alveolar
macrophages [28]. Our original findings indicate that CFTR
mRNA and protein are expressed in lung fibroblasts at levels
similar to those observed in macrophages. Dysregulated fibroblasts
Figure 4. Exaggerated proliferation and myofibroblast differentiation of CF fibroblasts. Cell proliferation and myofibroblast
differentiation in cultured lung (A–D) and skin (E–H) fibroblasts at the second passage purified from CF mice homozygous for the F508del
mutation and from wild-type (WT) mice. A,e) Uptake of 3H-thymidine (1 mCi/well) assessed in cultured cells seeded at 306103 cells/well, in the
absence of any added growth factor to culture media or in the presence of 1 to 100 ng/ml human rPDGF-BB for 1 h. After 48 h, adherent cells were
trypsinized before 3H-thymidine counting. Data expressed as counts per minute (cpm). b,f) Cell growth analysis assessed by daily counting, in a
Neubauer chamber, of trypsinized cells cultured in the absence of any added growth factor to culture media. c,g) a-SMA mRNA expression, using 18S
RNA as a reference, assessed in the absence of any added growth factor to culture media or in the presence of 1 to 100 ng/ml human rTGF-b1 for
24 h. d) a-SMA mRNA expression assessed in the presence of 0.1 to 50 mM vardenafil (Vard) for 6 h. h) Micrographs of fibroblast cultures under
stimulation with 10 ng/ml human rTGF-b1. Arrows identify formation of cellular aggregates. Bars: 100 mm. Values are means6 SEM of 3 multi(96)well
cultures per group from a representative experiment selected from at least 3 experiments with similar results. *: P,0.05; **: P,0.01; *** P,0.001 for
comparison of mean values.
doi:10.1371/journal.pone.0064341.g004
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can contribute to the pathogenesis of CF and may highlight
fibroblasts as a target for development of novel therapeutic
strategies. As CF dermal fibroblasts reproduce the basic dysfunc-
tional properties observed in lung fibroblasts, and because, unlike
lungs, skin is readily available and shows no secondary changes,
such as chronic infection and mucus obstruction, cultured
fibroblasts explanted from skin biopsies of CF patients could
Figure 5. Vardenafil prevents overresponsive proinflammatory status in CF fibroblasts. a,b–g) mRNA and c) protein expression of
proinflammatory cytokines in response to 0.1 mg/ml LPS in lung (a,b,e–g) and skin (c,d) cultured fibroblasts at the second passage purified from CF
mice homozygous for the F508del mutation and from wild-type (WT) mice. At the mRNA level, markers were assessed 3 h after LPS stimulation. At
the protein level, CCL-2 (c) was assessed 24 h after LPS stimulation. Vardenafil (Vard; 0.1 mM) was used for TNF-a (e), IL-1b (f) and IL-6 (g) mRNA
expression studies. 18S RNA used as a reference gene. Values are means 6 SEM of 3 multi(96)well cultures per group from a representative
experiment selected from at least 3 experiments with similar results. *: P,0.05; **: P,0.01; *** P,0.001 for comparison of mean values.
doi:10.1371/journal.pone.0064341.g005
Vardenafil, Inflammation and Fibrosis in CF
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represent a prime choice tissue to search for the primary defect
and to test efficacy of therapeutic strategies.
Our data show that vardenafil reduces overexpression of
proinflammatory and profibrotic markers, arguing that fibroblasts
represent target cells of the drug. While submicromolar concen-
trations appeared to influence proinflammatory and profibrotic
responses, much larger (10 mM) drug concentrations seemed to be
required to modulate myofibroblast differentiation with a-SMA
neoformation. The 0.1 mM concentration is clinically relevant
because it corresponds roughly to plasma levels measured 1 h after
administration of an oral therapeutic dose of 20 mg vardenafil to
healthy volunteers. Our data are consistent with a previous report
showing that sildenafil, a vardenafil analogue, reduces fibrosis in
the mdx mouse model of Duchenne muscular dystrophy [29]:
treating mdx mice with sildenafil reduced endomysial fibrosis and
TNF-a overexpression in diaphragm. In line with a recent paper
[30], our study highlights the potentiality of vardenafil to treat CF:
beside its ability to normalize the basic transepithelial chloride
transport defect [8,9], it modulates inflammation [10] and
fibrogenesis in CF.
This work provides novel insights into the contribution of
fibroblasts to the pathogenesis of CF. Fibroblasts could represent a
potentially attractive target for future trials and possible treatments
in CF. Moreover, this study provides compelling new support for
targeting cGMP signalling pathway in CF pharmacotherapy.
Supporting Information
Figure S1 Exaggerated inflammatory and fibrotic re-
sponses to bleomycin and preventing effect of vardenafil
in skin of CF mice. Histological sections of skin from wild-type
(a,b,e,f,i,j) and CF (c,d,g,h,k,l) mice homozygous for the F508del
mutation 21 days after treatement with saline (NaCl; a–d),
bleomycin (Bleo; e–h) or bleomycin and vardenafil (Bleo+Vard;
i–l) were stained with hematoxylin and eosin (a,c,e,g,i,k) or with
Masson’s trichrome (b,d,f,h,j,l). Representative micrographs from
3–4 mice per group. Bars correspond to 100 mm.
(PDF)
Figure S2 Extensive overproduction of inflammatory
mediators by CF lung fibroblasts. Responses of pro- and
anti-inflammatory markers to Pseudomonas aeruginosa lipopolysac-
charide (LPS, 0.1 mg/ml) or to F1/F2 stimulation in lung cultured
fibroblasts at the second passage purified from CF mice
homozygous for the F508del mutation and from wild-type (WT)
mice. a) CCL-2 protein assessed by ELISA, 24 h after stimulation
with 20 ng/ml mouse recombinant IL-1b stimulation. (b,c) TNF-
a, iNOS mRNA expression assessed 3 h after F1 polarization
induced by adding 0.1 mg/ml LPS plus 0.1mg/ml mouse
recombinant IFN-c. 18S RNA was used as a reference gene. (d)
Ym1-2 anti-inflammatory marker mRNA expression 3 h after F2
polarization induced by adding IL-4 plus IL-13 (10 ng/ml of each).
18S RNA was used as a reference gene. Values are means 6 SEM
of 3 multi(96)well cultures per group from a representative
experiment selected from at least 3 experiments with similar
results. *: P,0.05; **: P,0.01; *** P,0.001 for comparison of
mean values.
(PDF)
Methods S1 The detailed methods of cell cultures and skin
fibrosis model are proposed in Methods S1.
(DOC)
Table S1 Depicts the sequences of forward and reverse primers
used to perform quantitative RT-qPCR.
(DOC)
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